Philippe Cotelle

École Nationale Supérieure de Chimie de Lille — France

Medicine · Health Sciences

29h-index2.6kcitations145works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HIV/AIDS drug development and treatment(32), HIV Research and Treatment(20), Synthetic Organic Chemistry Methods(11), Hippo pathway signaling and YAP/TAZ(11), Chemical Synthesis and Reactions(10)

Publications145 total

Towards the design of ligands of the internal pocket TEADs C-terminal domain
European Journal of Medicinal Chemistry·2024
Development of LM-41 and AF-2112, two flufenamic acid-derived TEAD inhibitors obtained through the replacement of the trifluoromethyl group by aryl rings
Bioorganic & Medicinal Chemistry Letters·2023· 10 cited
Development of Lm-41 and Af-2112, Two Flufenamic Acid-Derived Tead Inhibitors Obtained Through the Replacement of the Trifluoromethyl Group by Aryl Rings
SSRN Electronic Journal·2023· 1 citedOpen Access
Crosstalk between the Hippo Pathway and the Wnt Pathway in Huntington’s Disease and Other Neurodegenerative Disorders
Cells·2022· 38 citedOpen Access
Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present)
Expert Opinion on Therapeutic Patents·2022· 47 citedOpen Access
Identification of potent inhibitors of arenavirus and SARS-CoV-2 exoribonucleases by fluorescence polarization assay
Antiviral Research·2022· 7 citedOpen Access
Toward the Design of Ligands Selective for the C-Terminal Domain of TEADs
Journal of Medicinal Chemistry·2022· 21 citedOpen Access
The NSP14/NSP10 RNA repair complex as a Pan-coronavirus therapeutic target
Cell Death and Differentiation·2021· 61 citedOpen Access
Discovery of a cryptic site at the interface 2 of TEAD – Towards a new family of YAP/TAZ-TEAD inhibitors
European Journal of Medicinal Chemistry·2021· 35 citedOpen Access
Design, Synthesis and Evaluation of a Series of 1,5‐Diaryl‐1,2,3‐triazole‐4‐carbohydrazones as Inhibitors of the YAP‐TAZ/TEAD Complex
ChemMedChem·2021· 18 cited
Meet Our Section Editor
Current Medicinal Chemistry·2019Open Access
Cyber Risk Management and Insurance: Cyber Scenario for the Aeronautics Industry, Market Response
HAL (Le Centre pour la Communication Scientifique Directe)·2019Open Access
Maîtrise du Risque Cyber et Assurance : Scénario cyber s’appliquant à la filière aéronautique
HAL (Le Centre pour la Communication Scientifique Directe)·2019Open Access
Metal chelators for the inhibition of the lymphocytic choriomeningitis virus endonuclease domain
Antiviral Research·2018· 10 cited
Meet Our Section Editor
Current Medicinal Chemistry·2018Open Access
Toward the Discovery of a Novel Class of YAP–TEAD Interaction Inhibitors by Virtual Screening Approach Targeting YAP–TEAD Protein–Protein Interface
Cancers·2018· 43 citedOpen Access
Targeting Transcriptional Enhanced Associate Domains (TEADs)
Journal of Medicinal Chemistry·2017· 97 citedOpen Access
Inhibition of hepatitis B virus replication by N -hydroxyisoquinolinediones and related polyoxygenated heterocycles
Antiviral Research·2017· 58 cited
Molecular Features of the YAP Inhibitor Verteporfin: Synthesis of Hexasubstituted Dipyrrins as Potential Inhibitors of YAP/TAZ, the Downstream Effectors of the Hippo Pathway
ChemMedChem·2017· 76 citedOpen Access
Meet Our Section Editor
Current Medicinal Chemistry·2016
page 1 of 8Next →

Frequent Co-authors

Fabrice Bailly(28), Zeger Debyser(9), Patricia Melnyk(9), Cédric Lion(7), Frauke Christ(7), Hervé Vezin(6), Gladys Mbemba(6), Jean‐Pierre Catteau(6), Muriel Billamboz(5), Christina Calmels(5), Marie‐Line Andréola(5), Jean‐François Mouscadet(5), Floriane Gibault(5), Cédric Maurin(5), Jean‐Pierre Hénichart(5), Myriam Witvrouw(4), Manon Sturbaut(4), Mathilde Coevoet(4), Virginie Suchaud(4), Frédéric Allemand(4)